Nouel Ana, Winter José Luis, Sepúlveda Luis
Departamento de Enfermedades Cardiovasculares, Clínica Alemana de Santiago, Santiago, Chile.
Rev Med Chil. 2022 Dec;150(12):1647-1654. doi: 10.4067/s0034-98872022001201647.
Heart failure (HF) is a global health problem. There is a strong association h between HF and type 2 diabetes mellitus (DM2), with an increasing prevalence of patients having both conditions concomitantly. Sodium-glucose cotransporter 2 inhibitors (ISGLT2) significantly reduce cardiovascular events, including cardiovascular death. In this article we will focus on the current evidence about the effectiveness of these medications in adults with heart failure with reduced or preserved ejection fraction.
心力衰竭（HF）是一个全球性的健康问题。HF与2型糖尿病（DM2）之间存在密切关联，同时患有这两种疾病的患者患病率不断上升。钠-葡萄糖协同转运蛋白2抑制剂（SGLT2）可显著降低心血管事件，包括心血管死亡。在本文中，我们将重点关注这些药物对射血分数降低或保留的成年心力衰竭患者有效性的现有证据。
